Bioactivity | PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases[1]. | ||||||
Invitro | PD-1/PD-L1-IN 3 (0.1 nM-10 μM) inhibits the binding of PD-1 and CD80 to PD-L1, with IC50s of 5.60 nM and 7.04 nM[1].PD-1/PD-L1-IN 3 blocks the binding of recombinant PD-L1-Ig to Jurkat-PD-1 cells, and also block binding of recombinant PD-1-Ig to either L2987 or LK35.2-hPD-L1, with IC50s of 26 nM, 12 nM, and 3.5 nM, respectively[1].PD-1/PD-L1-IN 3 (0.001-100 μM) promotes IFN secretion by CMV-specific T cells in a dose-dependent manner, with an EC50 of 400 nM[1]. | ||||||
Name | PD-1/PD-L1-IN 3 TFA | ||||||
Shortening | Maa-FANPHL-Sar-WSW-Nle-Nle-RCG (Disulfide bridge: Maa1-Cys15) | ||||||
Formula | C91H127F3N24O20S | ||||||
Molar Mass | 1966.19 | ||||||
Transport | Room temperature in continental US; may vary elsewhere. | ||||||
Storage | Sealed storage, away from moisture and light
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |